The Fact About ABBV-744 in combination with immunotherapy That No One Is Suggesting
In Segment C, participants will get ABBV-744 and oral navitoclax. In Phase D, individuals will acquire ABBV-744 and ruxolitinib. Participants will get treatment till sickness progression or even the contributors are unable to tolerate the study drugs.Ubiquitin-similar proteins that regulate the stability of critical Tremendous enhancer-mediated pro